298 related articles for article (PubMed ID: 28335891)
1. The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials.
Donia M; Kimper-Karl ML; Høyer KL; Bastholt L; Schmidt H; Svane IM
Eur J Cancer; 2017 Mar; 74():89-95. PubMed ID: 28335891
[TBL] [Abstract][Full Text] [Related]
2. The real-world impact of modern treatments on the survival of patients with metastatic melanoma.
Donia M; Ellebaek E; Øllegaard TH; Duval L; Aaby JB; Hoejberg L; Køhler UH; Schmidt H; Bastholt L; Svane IM
Eur J Cancer; 2019 Feb; 108():25-32. PubMed ID: 30605822
[TBL] [Abstract][Full Text] [Related]
3. Patterns of disease control and survival in patients with melanoma brain metastases undergoing immune-checkpoint blockade.
Milsch L; Gesierich A; Kreft S; Livingstone E; Zimmer L; Goebeler M; Schadendorf D; Schilling B
Eur J Cancer; 2018 Aug; 99():58-65. PubMed ID: 29906735
[TBL] [Abstract][Full Text] [Related]
4. Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma.
Sasse AD; Sasse EC; Clark LG; Ulloa L; Clark OA
Cochrane Database Syst Rev; 2007 Jan; (1):CD005413. PubMed ID: 17253556
[TBL] [Abstract][Full Text] [Related]
5. Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: A systematic review.
Spagnolo F; Picasso V; Lambertini M; Ottaviano V; Dozin B; Queirolo P
Cancer Treat Rev; 2016 Apr; 45():38-45. PubMed ID: 26975020
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
[TBL] [Abstract][Full Text] [Related]
7. [To outwit melanoma with its own tricks].
Bischoff A
MMW Fortschr Med; 2003 Apr; 145(15):4-6, 8, 10. PubMed ID: 15104255
[No Abstract] [Full Text] [Related]
8. Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care.
Goldman C; Tchack J; Robinson EM; Han SW; Moran U; Polsky D; Berman RS; Shapiro RL; Ott PA; Osman I; Zhong H; Pavlick AC; Wilson MA
Oncology; 2017; 93(3):164-176. PubMed ID: 28601879
[TBL] [Abstract][Full Text] [Related]
9. WITHDRAWN: Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma.
Sasse AD; Sasse EC; Clark LG; Clark OAC
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD005413. PubMed ID: 29409139
[TBL] [Abstract][Full Text] [Related]
10. Recent breakthroughs in metastatic uveal melanoma: a cause for optimism?
Sacco JJ; Kalirai H; Kenyani J; Figueiredo CR; Coulson JM; Coupland SE
Future Oncol; 2018 Jun; 14(14):1335-1338. PubMed ID: 29741103
[No Abstract] [Full Text] [Related]
11. [New hope in metastatic melanoma treatment?].
Guillot B
Ann Dermatol Venereol; 2012 Oct; 139(10):693-4. PubMed ID: 23122388
[No Abstract] [Full Text] [Related]
12. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition.
Laino AS; Woods D; Vassallo M; Qian X; Tang H; Wind-Rotolo M; Weber J
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581042
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant immunotherapy for melanoma.
Thomas D; Bello DM
J Surg Oncol; 2021 Mar; 123(3):789-797. PubMed ID: 33595889
[TBL] [Abstract][Full Text] [Related]
14. Ipilimumab in advanced melanoma: reports of long-lasting responses.
Farolfi A; Ridolfi L; Guidoboni M; Nicoletti SV; Piciucchi S; Valmorri L; Costantini M; Scarpi E; Amadori D; Ridolfi R
Melanoma Res; 2012 Jun; 22(3):263-70. PubMed ID: 22516968
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases.
Zaremba A; Philip M; Hassel JC; Glutsch V; Fiocco Z; Loquai C; Rafei-Shamsabadi D; Gutzmer R; Utikal J; Haferkamp S; Reinhardt L; Kähler KC; Weishaupt C; Moreira A; Thoms KM; Wilhelm T; Pföhler C; Roesch A; Ugurel S; Zimmer L; Stadtler N; Sucker A; Kiecker F; Heinzerling L; Meier F; Meiss F; Schlaak M; Schilling B; Horn S; Schadendorf D; Livingstone E
Eur J Cancer; 2021 Jul; 152():139-154. PubMed ID: 34102453
[TBL] [Abstract][Full Text] [Related]
16. Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma.
Shah DJ; Dronca RS
Mayo Clin Proc; 2014 Apr; 89(4):504-19. PubMed ID: 24684873
[TBL] [Abstract][Full Text] [Related]
17. Survival and prognostic factors in patients with brain metastases from malignant melanoma.
Meier S; Baumert BG; Maier T; Wellis G; Burg G; Seifert B; Dummer R
Onkologie; 2004 Apr; 27(2):145-9. PubMed ID: 15138346
[TBL] [Abstract][Full Text] [Related]
18. Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma.
Straatsma BR; Nusinowitz S; Young TA; Gordon LK; Chun MW; Rosen C; Seja E; Economou JS; Glaspy JA; Bozon V; Gomez-Navarro J; Ribas A
Am J Ophthalmol; 2007 Jun; 143(6):958-969. PubMed ID: 17434437
[TBL] [Abstract][Full Text] [Related]
19. Melanoma and immunotherapy.
Eggermont AM; Schadendorf D
Hematol Oncol Clin North Am; 2009 Jun; 23(3):547-64, ix-x. PubMed ID: 19464602
[TBL] [Abstract][Full Text] [Related]
20. Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011.
Luke JJ; Rubinstein LV; Smith GL; Ivy SP; Harris PJ
Melanoma Res; 2013 Apr; 23(2):152-8. PubMed ID: 23411478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]